1
|
Kim J, Lee J, Yoon D, Son M, Kim MJ, Ha S, Kim D, Yoo JA, Kim D, Chung HY, Moon HR, Chung KW. Thiobarbiturate-Derived Compound MHY1025 Alleviates Renal Fibrosis by Modulating Oxidative Stress, Epithelial Inflammation, and Fibroblast Activation. Antioxidants (Basel) 2023; 12:1947. [PMID: 38001800 PMCID: PMC10669799 DOI: 10.3390/antiox12111947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 10/24/2023] [Accepted: 10/26/2023] [Indexed: 11/26/2023] Open
Abstract
Chronic kidney disease (CKD) is a kidney structure and function abnormality. CKD development and progression are strongly influenced by oxidative stress and inflammatory responses, which can lead to tubulointerstitial fibrosis. Unfortunately, there are no effective or specific treatments for CKD. We investigated the potential of the thiobarbiturate-derived compound MHY1025 to alleviate CKD by reducing oxidative stress and inflammatory responses. In vitro experiments using NRK52E renal tubular epithelial cells revealed that MHY1025 significantly reduced LPS-induced oxidative stress and inhibited the activation of the NF-κB pathway, which is involved in inflammatory responses. Furthermore, treatment with MHY1025 significantly suppressed the expression of fibrosis-related genes and proteins induced by TGFβ in NRK49F fibroblasts. Furthermore, we analyzed the MHY1025 effects in vivo. To induce kidney fibrosis, mice were administered 250 mg/kg folic acid (FA) and orally treated with MHY1025 (0.5 mg/kg/day) for one week. MHY1025 effectively decreased the FA-induced inflammatory response in the kidneys. The group treated with MHY1025 exhibited a significant reduction in cytokine and chemokine expression and decreased immune cell marker expression. Decreased inflammatory response was associated with decreased tubulointerstitial fibrosis. Overall, MHY1025 alleviated renal fibrosis by directly modulating renal epithelial inflammation and fibroblast activation, suggesting that MHY1025 has the potential to be a therapeutic agent for CKD.
Collapse
Affiliation(s)
- Jeongwon Kim
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Jieun Lee
- Department of Manufacturing Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.L.); (D.Y.)
| | - Dahye Yoon
- Department of Manufacturing Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.L.); (D.Y.)
| | - Minjung Son
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Mi-Jeong Kim
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Sugyeong Ha
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Doyeon Kim
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Ji-an Yoo
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Donghwan Kim
- Functional Food Materials Research Group, Korea Food Research Institute, Wanju-gun 55365, Republic of Korea;
| | - Hae Young Chung
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| | - Hyung Ryong Moon
- Department of Manufacturing Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.L.); (D.Y.)
| | - Ki Wung Chung
- Department of Pharmacy, Research Institute for Drug Development, College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea; (J.K.); (M.S.); (M.-J.K.); (S.H.); (D.K.); (J.-a.Y.); (H.Y.C.)
| |
Collapse
|
2
|
Hwang HJ, Li DD, Lee J, Kang MK, Moon HR, Lee JH. Compounds That Have an Anti-Biofilm Effect against Common Bacteria at Very Low Concentrations and Their Antibiotic Combination Effect. Antibiotics (Basel) 2023; 12:antibiotics12050853. [PMID: 37237757 DOI: 10.3390/antibiotics12050853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 04/28/2023] [Accepted: 05/03/2023] [Indexed: 05/28/2023] Open
Abstract
Two synthetic compounds, MHY1383, azo-resveratrol and MHY1387, 5-[4-hydroxy-3,5-methoxybenzy]-2-thioxodihydropyrimidine-4,6[1H,5H]-dione have been reported to have an anti-biofilm effect on Pseudomonas aeruginosa at very low concentrations (1-10 pM). Here, we investigated the anti-biofilm effects of these compounds in various bacteria. We found that MHY1383 significantly inhibited Escherichia coli, Bacillus subtilis, and Staphylococcus aureus biofilm formation at 1 pM, 1 nM, and 10 nM, respectively. MHY1387 also inhibited the biofilm formation of E. coli, B. subtilis, and S. aureus at 1 pM, 10 nM, and 100 pM, respectively. Both MHY1383 and MHY1387 showed medium-dependent anti-biofilm effects on Salmonella enterica at high concentrations (10 μM). We also tested the susceptibility to antibiotics by measuring the minimum inhibitory concentration (MIC) in various bacteria. When P. aeruginosa, E. coli, B. subtilis, S. enterica, and S. aureus were treated with MHY1383 or MHY1387 in combination with four different antibiotics, the MICs of carbenicillin against B. subtilis and S. aureus were lowered more than two-fold by the combination with MHY1387. However, in all other combinations, the MIC changed within two-fold. The results of this study suggest that MHY1383 and MHY1387 are effective anti-biofilm agents and can be used at very low concentrations against biofilms formed by various types of bacteria. We also suggest that even if a substance that inhibits biofilm is used together with antibiotics, it does not necessarily have the effect of lowering the MIC of the antibiotics.
Collapse
Affiliation(s)
- Hyeon-Ji Hwang
- College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
- Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
| | - Dan-Dan Li
- College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
- Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
| | - Jieun Lee
- College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
| | - Min Kyung Kang
- College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
| | - Hyung Ryong Moon
- College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
- Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
| | - Joon-Hee Lee
- College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea
- Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
| |
Collapse
|
3
|
Lee S, Suh YJ, Lee Y, Yang S, Hong DG, Thirumalai D, Chang SC, Chung KW, Jung YS, Moon HR, Chung HY, Lee J. Anti-Inflammatory Effects of the Novel Barbiturate Derivative MHY2699 in an MPTP-Induced Mouse Model of Parkinson's Disease. Antioxidants (Basel) 2021; 10:antiox10111855. [PMID: 34829726 PMCID: PMC8615243 DOI: 10.3390/antiox10111855] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 11/19/2021] [Accepted: 11/20/2021] [Indexed: 11/16/2022] Open
Abstract
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, and is caused by the death of dopamine neurons and neuroinflammation in the striatum and substantia nigra. Furthermore, the inflammatory response in PD is closely related to glial cell activation. This study examined the neuroprotective effects of the barbiturate derivative, MHY2699 [5-(4-hydroxy 3,5-dimethoxybenzyl)-2 thioxodihydropyrimidine-4,6(1H,5H)-dione] in a mouse model of PD. MHY2699 ameliorated MPP⁺-induced astrocyte activation and ROS production in primary astrocytes and inhibited the MPP⁺-induced phosphorylation of MAPK and NF-κB. The anti-inflammatory effects of MHY2699 in protecting neurons were examined in an MPTP-induced mouse model of PD. MHY2699 inhibited MPTP-induced motor dysfunction and prevented dopaminergic neuronal death, suggesting that it attenuated neuroinflammation. Overall, MHY2699 has potential as a neuroprotective treatment for PD.
Collapse
Affiliation(s)
- Seulah Lee
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Yeon Ji Suh
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Yujeong Lee
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Cognitive Science Research Group, Korea Brain Research Institute, Daegu 41062, Korea
| | - Seonguk Yang
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Dong Geun Hong
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Dinakaran Thirumalai
- Department of Cogno-Mechatronics Engineering, College of Nanoscience and Nanotechnology, Pusan National University, Busan 46241, Korea; (D.T.); (S.-C.C.)
| | - Seung-Cheol Chang
- Department of Cogno-Mechatronics Engineering, College of Nanoscience and Nanotechnology, Pusan National University, Busan 46241, Korea; (D.T.); (S.-C.C.)
| | - Ki Wung Chung
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Young-Suk Jung
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Hyung Ryong Moon
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
- Department of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea
| | - Hae Young Chung
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
| | - Jaewon Lee
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan 46241, Korea; (S.L.); (Y.J.S.); (Y.L.); (S.Y.); (D.G.H.); (K.W.C.); (Y.-S.J.); (H.Y.C.)
- Research Institute for Drug Development, Pusan National University, Busan 46241, Korea;
- Correspondence: ; Tel.: +82-51-510-2805; Fax: +82-51-513-6754
| |
Collapse
|
4
|
Antipathogenic Compounds That Are Effective at Very Low Concentrations and Have Both Antibiofilm and Antivirulence Effects against Pseudomonas aeruginosa. Microbiol Spectr 2021; 9:e0024921. [PMID: 34494853 PMCID: PMC8557914 DOI: 10.1128/spectrum.00249-21] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Pseudomonas aeruginosa, a human pathogen, causes both acute and chronic infections that are mediated by virulence factor production and biofilm formation. Since both characteristics of P. aeruginosa are regulated by quorum sensing (QS), we screened 126 synthetic chemicals for anti-QS activity and finally selected the compounds that have both antivirulence and antibiofilm activities. To efficiently screen the chemical library, the following reporter-based bioassay systems were used: the QS- or biofilm-specific promoter-lacZ fusions (lasIp- or PA1897p-lacZ for the QS activity and cdrAp-lacZ for measuring the intracellular c-di-GMP levels). We also measured the production of virulence factors and biofilm formation in P. aeruginosa. A small-animal infection model using mealworms was also used for virulence analysis. From this screening, MHY1383 and MHY1387 were found to have both antivirulence and antibiofilm activities in P. aeruginosa. Most importantly, MHY1383 and MHY1387 exhibited these activities at very low concentrations, showing a significant anti-QS effect at 100 pM and an antibiofilm effect at 1 to 10 pM. By treating P. aeruginosa with these compounds, the virulence factor production and biofilm formation of P. aeruginosa were significantly reduced. These compounds can be developed as promising antipathogenic and antibiofilm drugs that can be applied in situations where such compounds must be used in an extremely low concentration. Our findings also offer a significant advantage for developing therapeutic agents with few adverse side effects. IMPORTANCE Many antibiotics are increasingly losing their efficacy due to antibiotic resistance mediated by biofilm formation. In this study, we screened a synthetic chemical library and discovered several compounds that have both antivirulence and antibiofilm effects against Pseudomonas aeruginosa, a notorious human pathogen. Two of them had these effects at extremely low concentrations and are expected not to develop resistance, unlike conventional antibiotics, because they have no effect on the growth of bacteria. Our results strongly suggest that these compounds act on the target in a noncompetitive manner, indicating that they are distinct from other previously known quorum sensing inhibitors or biofilm inhibitors. Our findings offer a significant advantage for developing therapeutic agents with few adverse side effects.
Collapse
|
5
|
6-Shogaol Mitigates Sepsis-Associated Hepatic Injury through Transcriptional Regulation. Nutrients 2021; 13:nu13103427. [PMID: 34684425 PMCID: PMC8540559 DOI: 10.3390/nu13103427] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 09/24/2021] [Accepted: 09/25/2021] [Indexed: 11/17/2022] Open
Abstract
Sepsis-associated liver dysfunction presents a significant public health problem. 6-Shogaol is the key bioactive component in dry ginger, which has antioxidant and anti-inflammation capacity. The present study aims to investigate the preventive effect of 6-shogaol on sepsis-induced liver injury. 6-Shogaol was administered to mice for 7 consecutive days before being intraperitoneally injected with lipopolysaccharide (LPS). After 24 h, mice were sacrificed, and biochemical and transcriptomic analyses were performed. Our results demonstrated that 6-shogaol prevented LPS-induced impairment in antioxidant enzymes and elevation in malondialdehyde level in the liver. The hepatic inflammatory response was significantly suppressed by 6-shogaol through suppressing the MAPK/NFκB pathway. RNA-sequencing data analysis revealed that 41 overlapped genes between the LPS vs. control group and 6-shogaol vs. LPS group were identified, among which 36 genes were upregulated, and 5 genes were downregulated for the LPS vs. control group. These overlapped genes are enriched in inflammation-related pathways, e.g., TNF and NFκB. The mRNA expression of the overlapped genes was also verified in the LPS-induced BRL-3A cell model. In summary, 6-shogaol shows great potential as a natural chemopreventive agent to treat sepsis-associated hepatic disorders.
Collapse
|
6
|
Liang Q, Liu H, Li XL, Yang Y, Hairong P. Rapid lipidomics analysis for sepsis-induced liver injury in rats and insights into lipid metabolic pathways using ultra-performance liquid chromatography/mass spectrometry. RSC Adv 2019; 9:35364-35371. [PMID: 35528052 PMCID: PMC9074727 DOI: 10.1039/c9ra05836b] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Accepted: 10/19/2019] [Indexed: 11/30/2022] Open
Abstract
Lipidomics has been applied in the identification and quantification of molecular lipids within an organism, and to provide insights into mechanisms in clinical medicine. Sepsis is a major systemic inflammatory syndrome and the liver here is a potential target organ for dysfunctional response. However, the study of alterations in global lipid profiles associated with sepsis-induced liver injury is still limited. In this work, we set out to determine alterations of lipidomics profiles in a rat model of sepsis-induced liver injury using an untargeted lipidomics strategy. Liquid chromatography coupled with mass spectrometry in conjunction with multivariate data analysis and pathway analysis were used to acquire a global lipid metabolite profile. Meanwhile, biochemistry index and histopathological examinations of the liver were performed to obtain auxiliary measurements for determining the pathological changes associated with sepsis-induced liver injury. Eleven lipid metabolites and two metabolic pathways were discovered and associated with sepsis-induced liver injury. The results indicated that various biomarkers and pathways may provide evidence for and insight into lipid profile alterations associated with sepsis-induced liver injury, and hence pointed to potential strategic targets for clinical diagnosis and therapy in the future. Lipidomics has been applied in the identification and quantification of molecular lipids within an organism, and to provide insights into mechanisms in clinical medicine.![]()
Collapse
Affiliation(s)
- Qun Liang
- ICU Center, First Affiliated Hospital, Heilongjiang University of Chinese Medicine Heping Road 24, Xiangfang District Harbin 150040 China +86-13069717715 +86-13069717715
| | - Han Liu
- Simon Fraser University (SFU) Burnaby British Columbia Canada
| | - Xiu-Li Li
- ICU Center, First Affiliated Hospital, Heilongjiang University of Chinese Medicine Heping Road 24, Xiangfang District Harbin 150040 China +86-13069717715 +86-13069717715
| | - Yang Yang
- ICU Center, First Affiliated Hospital, Heilongjiang University of Chinese Medicine Heping Road 24, Xiangfang District Harbin 150040 China +86-13069717715 +86-13069717715
| | - Panguo Hairong
- ICU Center, First Affiliated Hospital, Heilongjiang University of Chinese Medicine Heping Road 24, Xiangfang District Harbin 150040 China +86-13069717715 +86-13069717715
| |
Collapse
|